One of the earliest studies to evaluate the effectiveness of orally administered glyburide was published in 2000, finding no significant differences in maternal and perinatal outcomes in patients with GDM receiving glyburide treatment compared to those receiving insulin treatment [69]. This evidence concerns the gene INS and gestational diabetes.